Fast Alpha Activity in EEG of Patients With Alzheimer's Disease Is Paralleled by Changes in Cognition and Cholinergic Markers During Encapsulated Cell Biodelivery of Nerve Growth Factor.
Alzheimer’s disease
EEG
EEG alpha activity
choline acetyltransferase
encapsulated cell biodelivery
nerve growth factor
Journal
Frontiers in aging neuroscience
ISSN: 1663-4365
Titre abrégé: Front Aging Neurosci
Pays: Switzerland
ID NLM: 101525824
Informations de publication
Date de publication:
2022
2022
Historique:
received:
10
08
2021
accepted:
10
03
2022
entrez:
13
5
2022
pubmed:
14
5
2022
medline:
14
5
2022
Statut:
epublish
Résumé
Basal forebrain cholinergic neurons are dependent on nerve growth factor (NGF) for growth and survival and these cells are among the first to degenerate in Alzheimer's disease (AD). Targeted delivery of NGF has been suggested as a potential therapy for AD. This hypothesis was tested in a clinical trial with encapsulated cell biodelivery of NGF (NGF-ECB) in AD patients. Three of six patients showed improved biomarkers for cognition by the end of the study. Here, we report on the effects of targeted delivery of NGF on human resting EEG. NGF-ECB implants were implanted bilaterally in the basal forebrain of six AD patients for 12 months. EEG recordings and quantitative analysis were performed at baseline, 3 and 12 months of NGF delivery, and analyzed for correlation with changes in Mini-mental state examination (MMSE) and levels of the cholinergic marker choline acetyltransferase (ChAT) in cerebrospinal fluid (CSF). We found significant correlations between the topographic variance of EEG spectral power at the three study points (baseline, 3 and 12 months) and changes in MMSE and CSF ChAT. This possible effect of NGF was identified in a narrow window of alpha frequency 10-11.5 Hz, where a stabilization in MMSE score during treatment was related to an increase in EEG alpha power. A similar relation was observed between the alpha power and ChAT. More theta power at 6.5 Hz was on the contrary associated with a decrease in CSF ChAT during the trial period. In this exploratory study, there was a positive correlative pattern between physiological high-frequency alpha activity and stabilization in MMSE and increase in CSF ChAT in AD patients receiving targeted delivery of NGF to the cholinergic basal forebrain.
Sections du résumé
Background
UNASSIGNED
Basal forebrain cholinergic neurons are dependent on nerve growth factor (NGF) for growth and survival and these cells are among the first to degenerate in Alzheimer's disease (AD). Targeted delivery of NGF has been suggested as a potential therapy for AD. This hypothesis was tested in a clinical trial with encapsulated cell biodelivery of NGF (NGF-ECB) in AD patients. Three of six patients showed improved biomarkers for cognition by the end of the study. Here, we report on the effects of targeted delivery of NGF on human resting EEG.
Materials and methods
UNASSIGNED
NGF-ECB implants were implanted bilaterally in the basal forebrain of six AD patients for 12 months. EEG recordings and quantitative analysis were performed at baseline, 3 and 12 months of NGF delivery, and analyzed for correlation with changes in Mini-mental state examination (MMSE) and levels of the cholinergic marker choline acetyltransferase (ChAT) in cerebrospinal fluid (CSF).
Results
UNASSIGNED
We found significant correlations between the topographic variance of EEG spectral power at the three study points (baseline, 3 and 12 months) and changes in MMSE and CSF ChAT. This possible effect of NGF was identified in a narrow window of alpha frequency 10-11.5 Hz, where a stabilization in MMSE score during treatment was related to an increase in EEG alpha power. A similar relation was observed between the alpha power and ChAT. More theta power at 6.5 Hz was on the contrary associated with a decrease in CSF ChAT during the trial period.
Conclusion
UNASSIGNED
In this exploratory study, there was a positive correlative pattern between physiological high-frequency alpha activity and stabilization in MMSE and increase in CSF ChAT in AD patients receiving targeted delivery of NGF to the cholinergic basal forebrain.
Identifiants
pubmed: 35557841
doi: 10.3389/fnagi.2022.756687
pmc: PMC9085576
doi:
Types de publication
Journal Article
Langues
eng
Pagination
756687Informations de copyright
Copyright © 2022 Eyjolfsdottir, Koenig, Karami, Almqvist, Lind, Linderoth, Wahlberg, Seiger, Darreh-Shori, Eriksdotter and Jelic.
Déclaration de conflit d'intérêts
LW is an employee of NsGene and owns shares in the company. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Psychophysiol. 1996 Nov;24(1-2):61-100
pubmed: 8978436
J Neurosci Methods. 2007 Apr 15;161(2):342-50
pubmed: 17156848
Neurobiol Aging. 1989 Jan-Feb;10(1):75-87
pubmed: 2547172
Int J Mol Sci. 2021 May 27;22(11):
pubmed: 34071978
Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S1-5
pubmed: 12973744
J Alzheimers Dis. 2015;43(3):1059-72
pubmed: 25147108
J Neurosci. 1994 Oct;14(10):5986-95
pubmed: 7523630
Expert Rev Neurother. 2008 Nov;8(11):1703-18
pubmed: 18986241
Mol Med Rep. 2014 Oct;10(4):1739-45
pubmed: 25051506
J Neurosurg. 2012 Aug;117(2):340-7
pubmed: 22655593
Neurosci Lett. 1998 Sep 25;254(2):85-8
pubmed: 9779926
Brain Res. 2014 Apr 22;1559:11-25
pubmed: 24594019
Alzheimers Dement. 2015 Nov;11(11):1316-28
pubmed: 25676388
J Neural Transm Park Dis Dement Sect. 1992;4(1):79-95
pubmed: 1540306
Clin EEG Neurosci. 2009 Apr;40(2):129-42
pubmed: 19534305
Dement Geriatr Cogn Disord. 2015;39(3-4):132-42
pubmed: 25471612
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Dement Geriatr Cogn Disord. 1998 Sep-Oct;9(5):246-57
pubmed: 9701676
PLoS One. 2013 Jun 19;8(6):e65936
pubmed: 23840379
Am J Neurodegener Dis. 2014 Sep 06;3(2):72-83
pubmed: 25232512
Nat Med. 2005 May;11(5):551-5
pubmed: 15852017
J Alzheimers Dis. 2018;64(4):1359-1371
pubmed: 29991135
J Comp Neurol. 1988 Sep 8;275(2):216-40
pubmed: 3220975
Prog Neurobiol. 2006 Oct;80(3):114-28
pubmed: 17084014
Neuroimage. 2016 Aug 15;137:61-69
pubmed: 27222217
Clin Neurophysiol. 2007 Nov;118(11):2519-24
pubmed: 17892969
Clin Neurophysiol. 2008 Jun;119(6):1262-70
pubmed: 18424230
Trends Cogn Sci. 2012 Dec;16(12):606-17
pubmed: 23141428
Behav Brain Res. 2000 Nov;115(2):235-49
pubmed: 11000423
Dement Geriatr Cogn Disord. 2012;33(1):18-28
pubmed: 22377499
Alzheimers Dement. 2021 Sep;17(9):1528-1553
pubmed: 33860614
Electroencephalogr Clin Neurophysiol. 1988 Feb;69(2):110-7
pubmed: 2446830
Brain Res Bull. 1995;38(4):371-81
pubmed: 8535860
J Neurochem. 1996 Nov;67(5):2013-8
pubmed: 8863508
Comput Intell Neurosci. 2011;2011:938925
pubmed: 21403863
Clin Neurophysiol. 2007 Oct;118(10):2162-71
pubmed: 17765604